Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Study shows need for repeated vaccines for immunocompromised people

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, according to new research from the University of Cambridge led by a Gates Cambridge Scholar. The findings, published today in Science Advances, suggest that such individuals will need regular vaccine […]

Scholars win recognition for impact and engagement

Two Gates Cambridge Scholars have been recognised in the 2024 Cambridge Awards for Research Impact and Engagement. Stanley Onyemechalu [below right] was runner-up in the Early Career researcher category for his work on the Legacies of Biafra Heritage Project and Emma Houiellebecq was highly commended for her research on  strengthening the resilience of essential services […]

Exploring the origins of snake diversity in South America

“Snakes to me are the most beautiful creatures that exist. They look so simple, but they are so complex. They can glide, swim and burrow. They are so varied. I want people to see how amazing and beautiful snakes are,” says Andrés Alfonso-Rojas [2022]. His love of snakes has fuelled his PhD in Zoology.  Andrés […]

How do we learn languages?

Samuel Weiss-Cowie’s fascination with language learning began at the age of 15 when he started learning Korean. He is now in the third year of his PhD looking at how the brain learns a new language or new words in a native language. He says: “I wanted to see what was happening in the brain […]